Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

79.02 +0.97 (+1.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
A Look Into Gilead Sciences Inc's Price Over Earnings
Via Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
Is NASDAQ:GILD suited for dividend investing?
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied 
Via Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
Exposures Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying. 
Via Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
Via Benzinga
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's  
Via Benzinga
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
The biotech company makes three notable treatments for cancer. 
Via Investor's Business Daily
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook
Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.  
Via Benzinga
3 Pharma Stocks That Are Screaming Buys in October
Each company delivers an above-average dividend and revenue growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.